Johnson & Johnson's Tylenol Scare

5

10

25

30

35

40

45

50

commitment to putting safety first.

In 1982 the pharmaceutical company Johnson & Johnson (J&J) had experienced <u>a sharp increase in sales and earnings</u> and everything was **working out** just fine for Chief Executive Officer (CEO) James E. Burke and President David R. Clair. The year before J&J was number 68 on <u>the Fortune 500 list of the largest industrial companies in the U.S.</u> with sales of \$5.4 billion. The majority of the revenues were generated from <u>pharmaceutical</u>, <u>surgical and first-aid supplies</u>. <u>One the company's strongest products</u> was Tylenol, <u>an alternative drug to aspirin with lesser side effects</u>.

However, in the autumn of 1982, J&J experienced a major crisis when it was discovered that numerous bottles of its Extra-Strength Tylenol capsules had been laced with cyanide. By the end of the crisis, seven people had died. How J&J dealt with this situation set a new precedent for crisis management. The company was lauded for its quick decisions and sincere concern for its consumers. Despite initial losses, J&J regained and exceeded its previous market share within months of the incident.

The crisis started on September 30, 1982, when 3 people were reported dead in Chicago because of cyanide poisoning. Cyanide is an extremely dangerous poison that can kill a person within 15 minutes and as it turned out the cyanide was contained in Extra-Strength Tylenol capsules. The police and medical examiners retrieved Tylenol bottles from the houses of the deceased persons and discovered 10 other capsules with lethal doses. Within the next couple of days another 4 Chicago-area residents had died from taking Tylenol capsules with cyanide. It was discovered fairly quickly that the cyanide contamination in the capsules did not occur in the manufacturing process, that the tampering must had happened in Chicago, and that it was likely that a customer had purchased a bottle of Tylenol and returned it with cyanide injected into some of the capsules.

When J&J was faced with the initial situation, it had to make some tough decisions that would severely impact the future of the company. Rather than think in financial terms, however, CEO James Burke immediately turned to the company's Credo. Written by Robert Johnson in 1943, the document defines the focus of the company as its customers. With this as its inspiration, Tylenol used the media to promptly begin alerting people of the potential dangers of the product.

J&J then made a decision that would set a new standard for crises involving product tampering. The company ordered <u>a massive recall of more than 31 million bottles</u> at a cost of more than \$100 million. **It** also temporarily ceased all production of capsules and replaced **them** with <u>more tamperresistant caplets</u>. **This type of drastic response had** never been attempted, which prompted much criticism. However, J&J stood firm behind its decision - and for good reason. The company was able to "use the crisis to demonstrate to [its] customers [its] commitment to customer safety and to the quality of the Tylenol product." **In addition**, the company's willingness to be open with the <u>public and communicate with the media</u> helped the company maintain <u>a high level of credibility and customer trust</u> throughout the incident. Burke also maintained a high profile and repeatedly assured the public of the company's commitment to its customers' safety.

Directly following the incident, J&J's stock fell seven points, and it dropped from having 35 percent of the nonprescription pain-reliever market to having only eight percent of the market. However, these tough times would not last. The company aired commercials within days to regain the public's trust, and a month after the recall, the company embarked on an aggressive campaign to rebuild the Tylenol brand. In November, it promised to have the product back on the shelves in a new triple-tamper-resistant package -- the first of its kind -- by the end of the year. It offered incentives, such as a free replacement of caplets for the capsules and special coupons, to try to maintain its customer base. These attempts were successful, and by the following spring, J&J had regained its previous market share. But in early 1986, another poisoning occurred. A 23-year-old woman died after taking a cyanide-laced Tylenol capsule. J&J once again had to take action. The company quickly offered to replace all capsules with caplets (tablets in the shape of capsules). The effort cost J&J \$150 million. Despite the fact this case was soon identified as an isolated incident, J&J decided to permanently discontinue capsule products -- once again demonstrating its